Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:1098 (26 May), doi:10.1136/bmj.39164.568183.AE (published 23 April 2007)
Richard Holland, senior lecturer in public health medicine1, Iain Brooksby, medical director3, Elizabeth Lenaghan, senior research associate1, Kate Ashton, senior research associate1, Laura Hay, specialist registrar in public health medicine4, Richard Smith, reader in health economics1, Lee Shepstone, reader in medical statistics1, Alistair Lipp, director of public health5, Clare Daly, education pharmacist2, Amanda Howe, professor of primary care1, Roger Hall, professor of cardiology1, Ian Harvey, professor of epidemiology and public health1
1 Clinical Trials Unit, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich NR4 7TJ, 2 Academic Pharmacy Practice Unit, University of East Anglia, 3 Norfolk and Norwich University Hospital NHS Trust, Norfolk NR4 7UY, 4 Lothian NHS Board, 5 Great Yarmouth and Waveney Teaching Primary Care Trust, Great Yarmouth, Norfolk, NR14 8AB
Correspondence to: R Holland r.holland{at}uea.ac.uk
Design Randomised controlled trial.
Setting Home based intervention in heart failure patients.
Participants 293 patients diagnosed with heart failure were included (149 intervention, 144 control) after an emergency admission.
Intervention Two home visits by one of 17 community pharmacists within two and eight weeks of discharge. Pharmacists reviewed drugs and gave symptom self management and lifestyle advice. Controls received usual care.
Main outcome measures The primary outcome was total hospital readmissions at six months. Secondary outcomes included mortality and quality of life (Minnesota living with heart failure questionnaire and EQ-5D).
Results Primary outcome data were available for 291 participants (99%). 136 (91%) intervention patients received one or two visits. 134 admissions occurred in the intervention group compared with 112 in the control group (rate ratio=1.15, 95% confidence interval 0.89 to 1.48; P=0.28, Poisson model). 30 intervention patients died compared with 24 controls (hazard ratio=1.18, 0.69 to 2.03; P=0.54). Although EQ-5D scores favoured the intervention group, Minnesota living with heart failure questionnaire scores favoured controls; neither difference was statistically significant.
Conclusion This community pharmacist intervention did not lead to reductions in hospital admissions in contrast to those found in trials of specialist nurse led interventions in heart failure. Given that heart failure accounts for 5% of hospital admissions, these results present a problem for policy makers who are faced with a shortage of specialist provision and have hoped that skilled community pharmacists could produce the same benefits.
Trial registration number ISRCTN59427925 [controlled-trials.com] .
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses